Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. covers the month of September 2016. The company is a clinical-stage specialty biopharmaceutical firm focused on immunotherapy, specifically developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform for food allergies and other immune diseases. The filing primarily serves to announce upcoming management presentations at investor conferences.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a clinical-stage company, this document contains no financial performance data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document is informational regarding corporate communications and investor relations activities.
Guidance, Outlook, and Management Commentary
Management has scheduled presentations at four major investor conferences in September 2016 to discuss the company's strategy and pipeline:
- Citi's 11th Annual Biotech Conference: September 8, 2016, in Boston, MA (Charles Ruban, Susanna Mesa).
- Morgan Stanley Global Healthcare Conference: September 12, 2016, in New York, NY (Pierre-Henri Benhamou, David Schilansky, Susanna Mesa). A live webcast and replay will be available.
- Rodman & Renshaw 18th Annual Global Investment Conference: September 13, 2016, in New York, NY (Susanna Mesa).
- Bank of America Merrill Lynch Global Healthcare Conference: September 16, 2016, in London, UK (Pierre-Henri Benhamou, David Schilansky).
The company continues ongoing clinical trials for Viaskin Peanut and Viaskin Milk, preclinical development for Viaskin Egg, and a human proof-of-concept study for Viaskin Milk in treating Eosinophilic Esophagitis.
Key Facts for Investor Verification
- Verify the dates and times of the upcoming investor conference presentations listed above.
- Confirm the availability of the live webcast and replay for the Morgan Stanley conference on the company's investor relations website.
- Review the company's latest Form 20-F for actual financial data, as this 6-K contains no financial statements.
- Monitor the status of clinical trials for Viaskin Peanut and Viaskin Milk, which are central to the company's current valuation.